AGP Executive Report
Last update: 7 hours agoMassachusetts biotech and health care: Scholar Rock won its first FDA approval for Isembyld (apitegromab), a muscle-targeted spinal muscular atrophy therapy for patients 2 and older, after a prior FDA setback. Life sciences pipeline: Corbus Pharmaceuticals posted positive topline Phase 1b results for oral obesity drug CRB-913, showing about 5% average weight loss at 60 mg after 12 weeks, and Slate Medicines named Kenneth Koblan as Chief Scientific Officer. AI in the Bay State: Anthropic is opening a Cambridge office at One Kendall Square, while Acquia says CMOs and CIOs still can’t agree on who governs AI decisions. Energy and courts: Massachusetts utilities sued Hydro-Quebec over alleged power interruptions on a Maine transmission line, seeking tens of millions in damages. Housing and local projects: Massachusetts directed $18.2 million to Cambridge housing projects for 162 affordable units, and Connolly Brothers finished a renovation and addition at Endicott College’s Lodge in Beverly. Consumer and public safety: Spam loan calls are flooding phones, and Massachusetts communities are weighing surveillance tech like Flock license plate readers.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
